“ALS reversals”: demographics, disease characteristics, treatments, and co-morbidities

Affiliates Daniel Harrison [1], Paul Mehta [2], Michael A. van  Es [3], Elijah Stommel [4], Vivian E. Drory [5], Beatrice Nefussy [5], Leonard H. van den Berg [3], Jesse Crayle [1], Richard Bedlack [6], and The Pooled Resource Open-Access ALS Clinical Trial Consortium


[1] School of Medicine, Duke University
[2] Agency for Toxic Substances and Disease Registry, Division of Toxicology and Human Health Services
[3] Department of Neurology, University Medical Center Utrecht
[4] Department of Neurology, Geisel School of Medicine at Dartmouth
[5] Department of Neurology, Tel-Aviv Medical Center
[6] Department of Neurology, Duke University and Durham VA Medical Center

Journal Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
Summary This study aims to identify differences in demographics, disease characteristics, treatments, and co-morbidities between patients with ALS reversals and those with the usual progression of ALS. Findings indicated that ALS reversals were more likely to be seen in PALS that are male, have limb onset disease, and initially progress faster. Moreover, the odds of having taken curcumin, lutein, cannabidiol, azathioprine, copper, glutathione, vitamin D, and fish oil were higher for those with ALS reversal compared to controls.
Link to paper Find the paper here!